Malignant pleural mesothelioma exhibits characteristic changes in microRNA (miRNA) levels, and they are predominantly downregulated. Many have a tumour suppressor function; some are overexpressed and appear to function as onco-miRNAs. These changes in miRNA expression provide avenues to develop new therapeutic approaches.
Whilst the majority of miRNA studies in malignant pleural mesothelioma have focused on miRNA mimics, recent studies suggest that antisense inhibitors have similar potential. The recent FDA approval of the first siRNA therapy –together with ongoing clinical trials of a number of miRNA mimic drugs– means that gene silencing drugs have moved from concept to reality. Continued preclinical studies and early phase clinical trials are needed to determine the true potential of miRNA-targeting in the treatment of malignant pleural mesothelioma .
Another field of interest is CDKN2A/MTAP deletion; this is the most common copy number altera...
please login to read the entire article:
You need to register to read the entire article, please do so now.
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.